Clinical Trials Logo

NSCLC Stage II clinical trials

View clinical trials related to NSCLC Stage II.

Filter by:
  • None
  • Page 1

NCT ID: NCT04865250 Recruiting - NSCLC Stage IIIB Clinical Trials

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

iReP
Start date: January 7, 2021
Phase: Phase 2
Study type: Interventional

Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lung Cancer (NSCLC) to neoadjuvant ATEZOLIZUMAB plus Carboplatin/nab Paclitaxel Atezolizumab is given as intravenous infusion at a fixed dose of 1200 mg, day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase, Carboplatin at an initial dose of AUC (area under curve) 5 mg/mL/min, intravenously day 1 of each 21-day cycle for 3 cycles during the neoadjuvant treatment Phase, and Nab-Paclitaxel (Abraxane) at 100 mg/m2, intravenously day 1, 8 and 15 of each 21-day cycle for 3 cycles during the neoadjuvant treatment phase. Surgery after the 3rd cycle Atezolizumab / Carboplatin / Nab-Paclitaxel is standard procedure.

NCT ID: NCT04830826 Recruiting - NSCLC, Stage III Clinical Trials

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

Start date: June 10, 2020
Phase:
Study type: Observational

This study is a prospective, national, multi-center, non-interventional study. The main purpose is to explore the initial adjuvant treatment pattern after radical resection for early-stage NSCLC patients with EGFR Mutation-Positive in the real world. The secondary purpose was to observe the postoperative follow-up treatment pattern and its subgroups (based on different EGFR mutation status and different clinical stages).

NCT ID: NCT04205552 Recruiting - NSCLC, Stage I Clinical Trials

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

NEOpredict
Start date: March 4, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.

NCT ID: NCT03999710 Active, not recruiting - Lung Cancer Clinical Trials

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Start date: July 19, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.

NCT ID: NCT03454685 Recruiting - Healthy Subjects Clinical Trials

The Role of Microbiota on the Development of Lung Cancer

Start date: January 30, 2018
Phase:
Study type: Observational

Relationship between human microbiota and epidemiology of lung cancer

NCT ID: NCT01470716 Active, not recruiting - NSCLC, Stage IIIA Clinical Trials

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This study examines preoperative Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations.